MK-677 (Ibutamoren) vs Pramlintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MK-677 (Ibutamoren)
MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.
Full details →Pramlintide
Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.
Full details →Side-by-Side Comparison
| Aspect | MK-677 (Ibutamoren) | Pramlintide |
|---|---|---|
| Dose Range | 10 mg–25 mg | 15 mcg–120 mcg |
| Frequency | 1x daily | 3x daily |
| Cycle Length | 8–24 weeks | 12–52 weeks |
| Route | oral | subcutaneous |
| Mechanism | Acts as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects. | Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy. |
| Typical Dosage | Typical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase. | Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories. |
| Administration | Oral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing. | Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin. |
| Side Effects | Increased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity. | Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time. |
| Best For |
What They Have in Common
MK-677 (Ibutamoren), Pramlintide are both commonly used for:
Key Differences
Unique to MK-677 (Ibutamoren):
Which Has Stronger Evidence?
| Goal | MK-677 (Ibutamoren) | Pramlintide |
|---|---|---|
| Fat Loss | medium | medium |
Key Studies
MK-677 (Ibutamoren)
- Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.
Clinica chimica acta; international journal of clinical chemistry, 2026
- Hepatotoxicity induced by MK-677.
BMJ case reports, 2025
- Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
Basic & clinical pharmacology & toxicology, 2025
Pramlintide
- Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
Peptides, 2024
- Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.
The Journal of pharmacology and experimental therapeutics, 2024
- Pramlintide for post-bariatric hypoglycaemia.
Diabetes, obesity & metabolism, 2022
Ready to Learn More?
Looking for trusted sources?